Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.34 |
| ▸ | DRD2 | P14416 | 3/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.34 |
| ▸ | DRD1 | P21728 | 3/20 | 0.34 |
| ▸ | HTR2A | P28223 | 3/20 | 0.34 |
| ▸ | HTR2C | P28335 | 3/20 | 0.34 |
| ▸ | HTR7 | P34969 | 3/20 | 0.34 |
| ▸ | HRH1 | P35367 | 3/20 | 0.34 |
| ▸ | DRD3 | P35462 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7492940 | 0.83 | SLC6A3 (0.44) | SLC6A3ADRA2ADRD2ADRA2CDRD1 | |
| SCHEMBL7495913 | 0.81 | SLC6A3 (0.42) | SLC6A3ADRA2ADRD2DRD1HTR2A | |
| SCHEMBL3285100 | 0.76 | SLC6A3 (0.56) | SLC6A3DRD2 | |
| SCHEMBL7490563 | 0.76 | SLC6A3 (0.76) | SLC6A3DRD2HTR2CHRH1 | |
| SCHEMBL7493500 | 0.72 | SLC6A3 (0.57) | SLC6A3 | |
| SCHEMBL7494600 | 0.69 | SLC6A3 (0.44) | SLC6A3 | |
| SCHEMBL7544150 | 0.67 | SLC6A3 (0.61) | SLC6A3DRD2HTR2CHRH1 | |
| SCHEMBL6638545 | 0.66 | SLC6A3 (0.42) | SLC6A3ADRA2ADRD2DRD1HTR2A | |
| SCHEMBL3286314 | 0.61 | SLC6A3 (0.76) | SLC6A3DRD2HTR2CHRH1 | |
| SCHEMBL3285187 | 0.61 | SLC6A3 (0.76) | SLC6A3DRD2HTR2CHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1100803-B1 | PYRROLO [2,1-B] [1,3]BENZOTHIAZEPINES WITH ATYPICAL ANTIPSYCHOTIC ACTIVITY | SIGMA TAU IND FARMACEUTI (IT) | 2002-10-02 | — | — | EP | disclosed |
| US-6391870-B2 | DOPAMINERGIC AGENT | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-05-21 | — | — | US | disclosed |
| US-20020006921-A1 | Pyrrolo {2,1-b}{1,3}benzothiazepines with atypical antipsychotic activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-01-17 | — | — | US | disclosed |
| EP-1100803-A2 | PYRROLO 2,1-B] 1,3]BENZOTHIAZEPINES WITH ATYPICAL ANTIPSYCHOTIC ACTIVITY | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000006579-A2 | PYRROLO[2,1-B][1,3]BENZOTHIAZEPINES WITH ATYPICAL ANTIPSYCHOTIC ACTIVITY | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006921-A1 | Pyrrolo {2,1-b}{1,3}benzothiazepines with atypical antipsychotic activity | GABRE, GRIN2B, DRD1 | SLC6A3 155/4885ADRA2A 778/4885DRD2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.